MX9702473A - Parenteral pharmaceutical compositions containing gf120918a. - Google Patents

Parenteral pharmaceutical compositions containing gf120918a.

Info

Publication number
MX9702473A
MX9702473A MX9702473A MX9702473A MX9702473A MX 9702473 A MX9702473 A MX 9702473A MX 9702473 A MX9702473 A MX 9702473A MX 9702473 A MX9702473 A MX 9702473A MX 9702473 A MX9702473 A MX 9702473A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
gf120918a
compositions containing
parenteral pharmaceutical
safe
Prior art date
Application number
MX9702473A
Other languages
Spanish (es)
Other versions
MXPA97002473A (en
Inventor
Wei Qin Tong
Mickey Lee Wells
Original Assignee
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc
Publication of MX9702473A publication Critical patent/MX9702473A/en
Publication of MXPA97002473A publication Critical patent/MXPA97002473A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Pharmaceutical compositions that prevent or minimize precipitation upon injection or infusion, comprising: a) a safe and therapeutically effective amount of N-{4-[2-1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-ethyl]-phenyl} -9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide and its physiologically acceptable salts and solvates; b) a safe and effective amount of a surfactant; c) a buffer system; and d) a pharmaceutically acceptable carrier.
MXPA/A/1997/002473A 1994-10-05 1997-04-04 Parenteral pharmaceutical compositions containing gf1209 MXPA97002473A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31830894A 1994-10-05 1994-10-05
US318308 1994-10-05
PCT/US1995/012952 WO1996011007A1 (en) 1994-10-05 1995-10-04 Parenteral pharmaceutical compositions containing gf120918a
USUS95/12952 1995-10-04

Publications (2)

Publication Number Publication Date
MX9702473A true MX9702473A (en) 1997-07-31
MXPA97002473A MXPA97002473A (en) 1997-12-01

Family

ID=

Also Published As

Publication number Publication date
RU2157687C2 (en) 2000-10-20
BR9509251A (en) 1997-10-21
KR970705997A (en) 1997-11-03
HUT77883A (en) 1998-09-28
WO1996011007A1 (en) 1996-04-18
CZ104197A3 (en) 1997-09-17
EP0784474A2 (en) 1997-07-23
JPH10507177A (en) 1998-07-14
CA2201628A1 (en) 1996-04-18
NZ295546A (en) 1999-01-28
PL319511A1 (en) 1997-08-18
AU3891395A (en) 1996-05-02
AU702519B2 (en) 1999-02-25

Similar Documents

Publication Publication Date Title
MY132056A (en) Methods of inhibiting physiological conditions associated with an excess of neuropeptide y.
MX9805539A (en) Use of an antagonist of ppar-alpha and ppar-gamma for the treatment of syndrom x.
MX9701342A (en) Cosolvent parenteral formulation of tirilazad.
EP0647133A4 (en) Compositions and methods for enhanced drug delivery.
HUT75089A (en) Compositions containing hyaluronic acid or it's derivatives and pharmaceutical active agent
HK1008294A1 (en) (2-4-Disulfophenyl) n-tertiary butyl nitrone its salts and their use as pharmaceutical radical trapping agents
GB9016789D0 (en) Medicament administering devices
HUT57202A (en) Process for producing new pharmaceutically active 5-fluoro-2-///4-/cyclopropyl-methoxy/-2-pyridinyl/-methyl-sulfonyl/-1h-benzimidazol and pharmaceutical compositions containing them
MX9804850A (en) Antagonists of gonadotropin releasing hormone.
ZA964735B (en) Compositions and methods for topical administration of pharmaceutically active agents
KR100206481B1 (en) Galenic form for ocular administration and process for the preparation of same
GEP20043383B (en) Cell Adhesion-Inhibiting Antiinflammatory and Immune-Suppressive Compounds
MX9802150A (en) Inhibition of tumor necrosis factor alpha.
NZ218615A (en) S-(-)-1-propyl-2',6'-pipecoloxylidide hydrochloride monohydrate and local anesthesia compositions
EP0683668A4 (en) Compositions and methods for transdermal drug delivery.
UA37311C2 (en) Compound for treating sexual dysfunction and pharmaceutical composition
NZ295546A (en) Parenteral medicament containing n-{4-[2-1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-ethyl]-phenyl}- 9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide, surfactant, and buffer
IL105475A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 1a, 24(R) - DIHYDROXY-22(E)-DEHYDRO- VITAMIN D3 FOR TREATING OSTEOPOROSIS
GB2245831B (en) Drug delivery system for administering growth factors
IL105276A (en) (S)-a-PHENYL- 2-PYRIDINEETHANAMINE, ITS PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
IL112110A0 (en) Octahydro-1h-isoindoles and pharmaceutical compositions containing them
GB9321104D0 (en) Parenteral administration of altrenogest and compositions therefor
NZ233400A (en) 1,3-diazine derivatives and pharmaceutical compositions
ITMI911023A0 (en) PROCEDURE AND SYSTEM FOR THE FEEDING OF SPINNING MACHINES
MX9701529A (en) 1,1,2-triphenylbut-1-ene derivatives for treating alzheimers disease.